(Reuters) – Drugmaker Novartis has been hit by a slowdown in emerging markets, particularly in China, where previously double-digit growth has decelerated to mid-single digits, Chief Executive Joe Jimenez said in an interview with CNBC on Friday.
Jimenez’ comments echoed concerns expressed on Thursday by U.S. Federal Reserve Chair Janet Yellen, who said the outlook in emerging markets including China have led to volatility.
Despite the increasing risks, Jimenez said the Swiss company was not pulling back from emerging markets, rather relying on the strength of generics in China to drive business growth.
“So we are not pulling back. We’re in these markets for the long term. We are going to live through the volatility,” he said.
“We have seen a bit of a slowdown in emerging markets particularly China but in our business that means moving from mid-double digit growth rates to now in the mid-single digit growth rates,” he added. “If you think about the global healthcare market maybe growing at 2 or 3 percent this is still incremental growth.”
Novartis shares fell further after Jimenez’ comments, and were down 1.1 percent at 0900 GMT.
Novartis was still digesting acquisitions including from its $20 billion asset swap last year with GlaxoSmithKline, which bolstered the Basel-based company’s position in cancer drugs, among others.
Jimenez did not rule out further acquisitions.
“We’re looking at everything that’s out there,” he said. “The reason why Novartis hasn’t moved is that assets are very expensive right now and I think we’re going to hold our powder, we’re going to see what happens in the markets.” ($1 = 0.9573 Swiss francs) (Reporting by John Miller; Editing by Joshua Franklin and Susan Fenton)
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
